Expert Advice 2 Mar 2023
5 steps to strategic partnerships for healthtech startups
By Varvara Melikhova, founder and CEO of Unison Innovations Strategic partnerships are a better way to build a product’s capabilities…
Bristol-Myers Squibb
- Latest Posts
News and Trends 28 Nov 2022
Lyvgen and Bristol Myers Squibb commitment to transform cancer care
Lyvgen Biopharma announced yesterday that it has started a phase 2 trial of LVGN7409 plus docetaxel or, in collaboration with…
News and Trends 14 Oct 2022
A-Alpha Bio and Bristol Myers Squibb to collaborate on protein degradation
A-Alpha Bio, a synthetic biology and machine learning company that measures and engineers protein-protein interactions is to collaborate with Bristol…
News and Trends 15 Sep 2022
New research boosts Nordic Bioscience’s PRO-C6 as biomarker assay for trial enrichment in HFpEF
The New England Journal of Medicine Evidence (NEJME) has published research that further establishes and positions Nordic Bioscience’s extracellular matrix…
ADVERTISEMENT
News and Trends 12 Sep 2022
Treatment for adults with moderate to severe psoriasis approved by FDA
A treatment for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy has been approved by…
News and Trends 5 May 2022
Amphista Lands Megadeals to Smash Cancer using Protein Degradation
As big pharma companies flock to drugs that destroy harmful proteins, the UK protein degradation specialist Amphista Therapeutics has bagged…
News and Trends 29 Apr 2021
BMS’s Cancer Trial Showcases Potential for Checkpoint Inhibitors
Bristol Myers Squibb’s recent phase III success provided the first late-stage confirmation for a novel immune checkpoint target in nearly…
In Depth 9 Apr 2018
Are PD-1 and PD-L1 Checkpoint Inhibitors As Good As We Thought?
Checkpoint inhibitors, especially those targeting PD-1 and PD-L1, are exploding in popularity. But how much of it is hype? The…
News and Trends 28 Mar 2017
Why did Biotech Beat Pharma to Bring the First Gene Therapy to Market?
Pharma would seemingly best biotech in any competition. A few CEOs explain why it left the honor of “The First Gene Therapy”…
News and Trends 20 Mar 2017
Will BMS Take Over a Danish Biotech in a Massive €400M Deal?
Galecto Biotech has presented positive data from a Phase II study with its pulmonary fibrosis candidate, giving BMS the option…
ADVERTISEMENT
News and Trends 6 Feb 2017
French Biotech’s Checkpoint Inhibitor Fails Phase II Leukemia Trial
Innate Pharma's checkpoint inhibitor candidate lirilumab missed its primary endpoint in a Phase II trial, which gave a hard blow…
News and Trends 26 Dec 2016
The Largest Deals, Fundraising and Exits of 2016 in European Biotech
Curious about which technologies have attracted the most cash in biotech finance this year? Here's a list of the most impressive cash…
News and Trends 22 Dec 2016
BMS Offers €850M for a British Oncolytic Virus better than CAR-T
BMS is offering PsiOxus Therapeutics a massive deal to get exclusive rights of an oncolytic virus that could outperform the…
News and Trends 16 Nov 2016
Microbiomics recruited for Immuno-Oncology in a Huge New Partnership
What if the bacteria in your gut could help fight cancer? Enterome is partnering with Bristol-Myers Squibb to explore this…
News and Trends 7 Nov 2016
Results from 45% of Clinical Trials are kept Secret
A new transparency study has identified Sanofi, Novartis and GSK as the companies that keep the most clinical trial results unreported.…
News and Trends 17 Oct 2016
It’s not over yet for Opdivo; AbbVie takes a stand in Leukemia
The Committee on Medicinal Products for Human Use (CHMP) has handed down a pair of positive opinions of Opdivo and…
ADVERTISEMENT
News and Trends 10 Oct 2016
Big Pharmas Battle to be the Lung Cancer Leader at ESMO
Merck, Roche and BMS have unveiled updated results in Copenhagen as the companies duke it out for the leadership in…
News and Trends 7 Jul 2016
BMS to acquire Swedish Immuno-Oncology Biotech for €460M
Bristol-Myers Squibb wants to strengthen its immuno-oncology even further. For this, it is acquiring Cormorant - a Biotech developing immunotherapies in…
News and Trends 1 Jul 2016
BMS to combine Immuno-Oncology Blockbuster with Oxford Biotech
Oxfordshire based PsiOxus will team up with the Immuno-Oncology Giant, Bristol-Myers Squibb, to test the combinatorial effect of their blockbuster…
News and Trends 7 Jun 2016
New Massive €250M Investment Fund Closed for European Biotech
Life Sciences Partners (LSP) has closed its new life sciences fund, 'LSP5'. The fund surpassed its €152M target and reached…